Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycosides--50 years on

E J Begg1, M L Barclay

  • 1Department of Clinical Pharmacology, Christchurch School of Medicine, New Zealand.

British Journal of Clinical Pharmacology
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).

Alimentary pharmacology & therapeutics·2018
Same author

Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2018
Same author

Lichen sclerosus in pregnancy: presentation of two cases.

Journal of lower genital tract disease·2015
Same author

Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.

The pharmacogenomics journal·2015
Same author

The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance.

Annals of clinical biochemistry·2013
Same author

Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital.

Internal medicine journal·2013
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Aminoglycoside antibiotics, crucial for serious infections, are evolving. New once-daily dosing strategies aim to improve efficacy and reduce toxicity, marking a significant shift in their clinical use.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Antibiotic Therapy

Background:

  • Aminoglycoside antibiotics have been used for 50 years.
  • Key factors for their success include rapid bactericidal effect, synergy with beta-lactams, clinical effectiveness, low resistance rates, and cost-effectiveness.
  • They remain first-line treatments for severe Gram-negative infections, sepsis, and bacterial endocarditis.

Observation:

  • Nephrotoxicity and ototoxicity are significant clinical drawbacks of aminoglycosides.
  • Traditional dosing strategies focused on reducing toxicity through therapeutic drug monitoring and specific target concentrations.
  • Recent shifts involve larger, less frequent doses, exemplified by once-daily aminoglycoside dosing.

Findings:

  • Once-daily aminoglycoside dosing represents a paradigm shift in administration.

Related Experiment Videos

  • This approach holds promise for enhanced therapeutic efficacy.
  • Potential benefits include reduced patient toxicity and simplified administration and monitoring protocols.

    • Implications:

    • The evolution of aminoglycoside dosing strategies impacts clinical practice for serious bacterial infections.
    • Once-daily dosing may optimize the therapeutic index of these vital antibiotics.
    • Further research and clinical adoption of new dosing regimens are anticipated.